With strong leaps towards 2025
14/09/21 -"Our SOTP valuation was clearly helped by the higher multiple reference that we now apply to Life Science, lifting the EV/EBIT multiple from 18.0x to 18.5x. To Healthcare, we now apply an EV/EBIT ..."
Pages
81
Language
English
Published on
14/09/21
You may also be interested by these reports :
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...
16/04/24
Preview: Positive 1Q24 driven by clinical developments of portfolio companies
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...
15/04/24
Turnaround story on track – TP increased to CHF 30.00 (from CHF 25.00) – Add reiterated